Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma

NCT ID: NCT01584726

Last Updated: 2014-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency

follow asthma severity score and length of stay

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

magnesium sulfate arm

magnesium sulfate with standard therapy

Group Type OTHER

Magnesium Sulfate

Intervention Type DRUG

single dose of magnesium sulfate nebulization

placebo arm

placebo with standard therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate

single dose of magnesium sulfate nebulization

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric asthma patients with moderate to severe exacerbation

Exclusion Criteria

* Known allergy to magnesium sulfate
* History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
* Use of oral steroid medication within 72 hours of presentation
* Radiographic evidence of pneumonia at presentation
* Administration of intravenous magnesium sulfate prior to study enrollment
Minimum Eligible Age

2 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hamad Medical Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

KHALID AL ANSARI, MD

Role: PRINCIPAL_INVESTIGATOR

SENIOR CONSULTANT-HEAD OF PEDIATRIC EMERGENCY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamad Medical Corporation

Doha, Qatar, Qatar

Site Status RECRUITING

Pediatric Emergency Centre

Doha, , Qatar

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Qatar

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Khalid Al Ansari, MD,FRCP,FAAP

Role: CONTACT

97444396001 ext. 6006

Dr. Wessam Mouharam, MD

Role: CONTACT

97444396022 ext. 6012

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

KHALID AL ANSARI, MD,FRCP,FAAP

Role: primary

+974 44396006 ext. 6001

WESSAM MOUHARAM, MD

Role: backup

+97444396022 ext. 6012

KHALID AL ANSARI, MD,FRCP,FAAP

Role: primary

97444396022 ext. 6006

WESSAM MOUHARAM, MD

Role: backup

9744396022 ext. 6012

References

Explore related publications, articles, or registry entries linked to this study.

Alansari K, Ahmed W, Davidson BL, Alamri M, Zakaria I, Alrifaai M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. Pediatr Pulmonol. 2015 Dec;50(12):1191-9. doi: 10.1002/ppul.23158. Epub 2015 Feb 4.

Reference Type DERIVED
PMID: 25652104 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

#12095/12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Intake of Mg in Controlled Asthmatic Patients
NCT06721247 ACTIVE_NOT_RECRUITING PHASE2/PHASE3
Montelukast With Status Asthmaticus, Ages 6-18
NCT00494572 UNKNOWN PHASE2/PHASE3